THERAPY DOSSIER · th-9dea855ef86b

Helix B surface peptide (HBSP)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28365917 ↗2017Reported benefit

The Protective Effects of Helix B Surface Peptide on Experimental Acute Liver Injury Induced by Carbon Tetrachloride.

MixedChemical/toxinC57BL/6Intraperitoneal8 nmol/kg2 h after carbon tetrachloride administration

Model: Acute liver injury induced by carbon tetrachloride administration; serum and liver sampled 24 h after injury

HBSP significantly reduced serum transaminases, lactate dehydrogenase and hepatic pro-inflammatory cytokines, decreased CD3, CD8 and CD68 positive cell numbers and cleaved caspase-3, and reduced apoptosis in vivo. Survival of mice with acute liver injury was increased, and this benefit was abolishe…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…